ArticleScientific reports2023

A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.

Ruilin Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.